Clarivate

MAY 14, 2024

With only two3 GLP-1 drugs currently approved for weight loss—Huadong Medicine’s version of daily dosed liraglutide and thrice-a-day dosed beinaglutide from Benamae Pharma—the gap is substantial and leaves a solid market opportunity for weight loss drugs. What’s leading to the boom in development of semaglutide biosimilars?

Manufacturing 52

Manufacturing Marketing Leads Medicine 52

PM360

MAY 10, 2024

May 9, 2024 /PRNewswire/ — VUE Health, a Boston-based healthcare advertising agency, has hired Zara Baker as Chief Digital Innovation Officer. Before that, she was the head of omnichannel strategy at Ionis Pharma and held senior digital roles at various healthcare and biopharma companies.

Healthcare 52

Healthcare Healthcare Biopharma Engineering 52

pharmaphorum

JANUARY 24, 2023

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.

Medicine 96

Medicine Healthcare Healthcare Pharma 96

PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This allows for a complementary portfolio fit without the kind of competitive overlap that comes under regulatory scrutiny from the FTC.

Biopharma 111

Biopharma Pharma Marketing Management 111

pharmaphorum

JANUARY 16, 2023

China’s Luye Pharma has claimed its first FDA approval, getting a green light for Rykindo, an injectable formulation of the antipsychotic risperidone given every two weeks. Analysts at GlobalData said last year that they expect LY03010 to launch in 2024 and bring in sales of around $64 million in 2030.

FDA 52

FDA Pharma Marketing Competition 52

European Pharmaceutical Review

JULY 18, 2022

Nebido is also patented until March 2024 in the European Union and until May 2027 in the United States. The deal is expected to close by the end of 2022, subject to approval by the relevant competition authorities. The long-acting injectable treatment for testosterone deficiency has been commercially approved in more than 80 countries.

Medicine 80

Medicine Physicians Competition Patients 80

Star OUTiCO

DECEMBER 11, 2023

Being part of Uniphar, we’ve got so many resources and experts across all areas of pharma and medtech, and specialisms under that. Going forward into 2024 there are some exciting things which I’m keen to get stuck into. Candidates really need to set themselves apart from their competition.

Recruitment 52

Recruitment Consulting Competition Specialization 52

PM360

SEPTEMBER 21, 2023

Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. In 2024, ARPA removes the 100% AMP cap.

Management 105

Management Manufacturing Sales Competition 105

PM360

APRIL 7, 2023

However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. pharma sales in 2020) and the size of 340B discounts (25-50%), companies may see significantly reduced revenues for important products.

Manufacturing 97

Manufacturing Insurance Government Marketing 97

PM360

DECEMBER 20, 2023

Learn more about why each company went with its respective strategy and the current outlook for each company in 2024 and beyond. The deal is expected to close in 2024. Many investors also prioritize companies with a substantial market opportunity and a unique product, particularly in competitive markets or crowded therapeutic areas.

Management 109

Management Marketing Healthcare Healthcare 109

Clarivate

MAY 8, 2024

A glance at the 2023 and early 2024 life science dealmaking environment shows fewer, but higher-value, transactions. Other partnerships of note include one for a couple of Shanghai-based Elpiscience Biopharma Ltd’s preclinical bispecific antibody assets, licensed by Tokyo-based Astellas Pharma Inc, with the option to license two more.

Pharma 59

Pharma Biopharma Prospecting Competition 59

PM360

NOVEMBER 13, 2023

Improving healthcare and patient outcomes requires that stakeholders communicate and collaborate, and GoodRx is one of the few places where providers, patients, and pharma can connect every single day. Is GoodRx in Your 2024 HCP Marketing Plan? How are they different? However, once your competitors read this article, that may not last.

Media 52

Media Prescription Healthcare Provider Patients 52

pharmaphorum

NOVEMBER 25, 2022

The Parma site, as yet only nine months into construction, is due to become operational from 2024, with FDA, IFA, and EMA approvals due to be sought for 2025. In brief, the European plan for Chiesi is in-house drug development of biologicals and rare disease targeting. The situation was reversed only 25 years ago.

Pharmaceutical 97

Pharmaceutical Manufacturing Medicine Competition 97

European Pharmaceutical Review

NOVEMBER 30, 2023

For example, the GMP report stated that the contract development and manufacturing organisation (CDMO) eXmoor pharma, will be launching a cell and gene therapy process development and clinical manufacturing facility in Bristol. Licensing of the manufacturing suites is expected in early 2024.

Manufacturing 75

Manufacturing Recruitment Medicine Biopharma 75

PM360

APRIL 22, 2024

There is a fantastic opportunity for medical teams to become a unifying force in pharma, working in unison commercial teams to define customer journeys that ensure physicians receive a much more connected and less disparate experience. Gamification and simulation-based training modules foster active learning experiences for HCPs.

Education 59

Education Physicians Healthcare Healthcare 59

PM360

FEBRUARY 1, 2024

As we step into 2024, these insights pave the way for understanding the industry’s trajectory in the near future. Implications for Biotech in 2024 and Beyond The survey findings serve as a compass, guiding the biotech sector towards a future entrenched in collaboration, strategic funding, and innovation.

Recruitment 52

Recruitment Healthcare Healthcare Management 52

pharmaphorum

JULY 19, 2022

The Swiss pharma group said last October that it was looking into the future of Sandoz, which could include a range of options, including retaining, spinning off and selling the business. billion off its costs by 2024, up from its earlier estimate of $1 billion, that will see 8,000 jobs shed worldwide. Planned cost-savings now $1.5

Sales 98

Sales Competition Medicine Pharma 98

Pharmaceutical Technology

SEPTEMBER 26, 2022

Both Sandoz and Novartis are internationally renowned pharma companies, with a combined 34 production facilities worldwide. Strong competition limits Sandoz's growth. Production facilities highlight differences in drug focus. The site employs around 250 people. The company had revenues of $9.6bn both in 2020 and last year.

Competition 64

Competition Manufacturing Marketing Distribution 64

pharmaphorum

JUNE 29, 2022

The layoffs – originally reported by TagesAnzeiger and citing unnamed sources – are part of a cost-reduction programme announced in April aimed at trimming at least $1 billion by 2024 off the group’s annual expenditures. If confirmed, the reductions would be equivalent to around 7.4%

Sales 97

Sales Competition Management Marketing 97

Evolve Your Success

APRIL 11, 2023

He reflects on his early career in pharma and B2B sales, and how it led him to his entrepreneurship journey. He had a small stint in pharma at the very beginning of his career and even had a stint in B2B sales right out of college. They don’t know what pharma or diagnostics is. I’m not a pharma guy.

Sales 52

Sales Medical Medical sales Media 52

pharmaphorum

JANUARY 4, 2023

It has been proposed that the amount of these fees charged by the data holder must be transparent, proportionate, and “must not restrict competition” 10. The EC is hoping that, by the end of its current mandate on 31 October 2024, the legislative process will be completed, with the EHDS becoming operational in 2025.

Pharmaceutical 95

Pharmaceutical Electronics Healthcare Healthcare 95

PM360

DECEMBER 20, 2023

A significant battle for the hearts and minds of healthcare professionals (HCPs) will play out in social media during 2024. HCPs are pressed for time, eager to keep up with scientific and clinical developments, skeptical about big pharma, and increasingly focused on outcomes and metrics. Look for TikTok to merchandise the 4.7

Media 122

Media Physicians Pharma reps Pharma Rep 122

Pharmaceutical Technology

JANUARY 25, 2023

In such times, experts expect partnerships between biotechs and big pharma, like the Anima Biotech/AbbVie deal announced earlier this month , to become even more popular. Surviving a tough biotech market In the backdrop of these challenges, companies may prioritise licensing and partnerships with larger pharma earlier than usual, says Lyne.

Marketing 69

Marketing Biopharma Pharma Competition 69

Pharmaceutical Technology

DECEMBER 4, 2022

Others are made by big pharma giants like Boehringer Ingelheim , Novartis , or Pfizer , which has raised the expectations for a competitive market. . Samsung Bioepis and Organon previously stated that Hadlima's interchangeability data should be ready in 2024. Biosimilar uptake could be more gradual.

Marketing 104

Marketing Physicians Competition Patients 104

Pharmaceutical Technology

DECEMBER 19, 2022

by the end of 2023 and may continue to rise in 2024 to 5%. Most pharmas will buy biotech companies or smaller pharma groups for the quality of their clinical assets and the drugs on their developments,” he says. JP Morgan predicts that the US unemployment rate could rise to 4.3%

Pharmaceutical 69

Pharmaceutical Manufacturing Government Medicine 69

Pharmaceutical Technology

FEBRUARY 17, 2023

The agency proposes that pharma move away from the common maximum tolerated dose (MTD) to trial designs that prioritise drug dosage optimisation at different stages. In 2021, Amgen agreed to conduct a Phase II study (NCT04933695), which is supposed to complete in May 2024, according to Clinicaltrials.gov.

FDA 115

FDA Side effects Pharmacology Patients 115

Pharmaceutical Technology

APRIL 24, 2023

GlobalData predicts that Comirnaty’s sales will increase by more than 20% between 2024 and 2027. We want this product to go to clinic, but we are more into designing the nanocarrier right now, so the sooner a big pharma takes them [the nanocarriers] for further development, the better,” he says.

Medicine 59

Medicine Pharmaceutical FDA Sales 59

Pharmaceutical Technology

JUNE 15, 2023

By the end of the year, the company will seek to identify similar issues in European biosimilars, followed by the Middle East and Africa in Q1 2024, and Asia Pacific in Q2. The latter also impacted Canada and Brazil. Free Report How is the Biopharmaceutical industry evolving?

Education 52

Education Patients Healthcare Healthcare 52